Related Experiment Video
Updated: Nov 12, 2025
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.5K
Biased agonism at G protein-coupled receptors
1College of Medicine, QU Health, Qatar University, Doha, Qatar; Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha, Qatar.
Cellular Signalling
|March 21, 2021
Summary
Discovering biased agonists for G protein-coupled receptors (GPCRs) offers a path to develop safer drugs. This research explores biased agonism to create pathway-selective therapeutics with fewer side effects.
Area of Science:
- Pharmacology
- Biochemistry
- Drug Discovery
Background:
- G protein-coupled receptors (GPCRs) are key therapeutic targets, but their ligands often cause side effects due to activating multiple signaling pathways.
- Biased agonism proposes developing pathway-selective drugs to improve therapeutic outcomes and reduce adverse events.
- Identifying and quantifying biased agonists is challenging due to complex signaling and unclear molecular mechanisms.
Discussion:
- This special issue reviews recent advancements in discovering and optimizing biased ligands for various GPCRs.
- It highlights novel insights into biased agonism while acknowledging conceptual and experimental limitations for drug discovery.
- Understanding biased signaling is crucial for developing more effective and tolerable therapeutics.
Key Insights:
- Biased agonism aims to dissociate desired therapeutic effects from unwanted side effects by targeting specific signaling pathways.
- Quantifying ligand bias requires careful control of confounding factors and a deeper understanding of molecular mechanisms.
- The development of biased agonists holds promise for personalized medicine and improved patient outcomes.
Outlook:
- Future research should focus on elucidating the molecular underpinnings of biased signaling to refine drug discovery strategies.
- Continued exploration of biased agonism in GPCRs may lead to novel therapeutics with improved safety profiles.
- Bridging conceptual and experimental gaps is essential for translating biased agonism into clinical success.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
9.2K
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.8K
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
3.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.4K
01:29The Two-State Receptor Model
2.8K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.8K
01:09GPCRs Regulate Adenylyl Cylase Activity
6.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.3K
01:22Activation and Inactivation of G Proteins
8.6K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
8.6K
01:21G-protein Coupled Receptors
128.0K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
128.0K
01:29Drug-Receptor Interactions
6.8K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.8K